Tumor Necrosis Factor-α Inhibition Before and After Rituximab Treatment in Juvenile Idiopathic Arthritis: What Shall We Expect? A Pilot Study

J Rheumatol. 2022 Jun;49(6):654-656. doi: 10.3899/jrheum.211039. Epub 2022 Mar 15.

Authors

Achille Marino¹, Francesco Orsini², Francesca Pregnolato³, Rolando Cimaz^{4

3}

Affiliations

¹ Unit of Pediatric Rheumatology, ASST Gaetano Pini-CTO; achille.marino@asst-pini-cto.it.
² University of Milan.
³ Department of Clinical Sciences and Community Health, and Research Center for Adult and Pediatric Rheumatic Diseases, University of Milan, Milan, Italy.
⁴ Unit of Pediatric Rheumatology, ASST Gaetano Pini-CTO.

PMID: 35293329
DOI: 10.3899/jrheum.211039

No abstract available

MeSH terms

Antirheumatic Agents* / therapeutic use
Arthritis, Juvenile* / drug therapy
Humans
Pilot Projects
Rituximab / therapeutic use
Tumor Necrosis Factor-alpha

Substances

Antirheumatic Agents
Tumor Necrosis Factor-alpha
Rituximab